Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 21:11:757196.
doi: 10.3389/fonc.2021.757196. eCollection 2021.

Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study

Zaoqin Yu  1 , Rui Huang  2 , Li Zhao  3 , Ximin Wang  1 , Xiaofang Shangguan  2 , Wei Li  1 , Min Li  1 , Xianguo Yin  3 , Chengliang Zhang  1 , Dong Liu  1
Affiliations

Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study

Zaoqin Yu et al. Front Oncol. .

Abstract

Background: Oxaliplatin (OXA), a third-generation platinum derivative, has become one of the main chemotherapeutic drugs for colorectal cancer and other cancers, but reports of adverse reactions are also increasing with the extensive application of OXA. In this study, post-marketing surveillance was carried out to investigate the safety profile of OXA in a real-world setting in Chinese cancer patients to provide a reference for the rational application of OXA.

Methods: All patients with cancer who received OXA-based chemotherapy in 10 tertiary hospitals in Hubei Province, China, between May 2016 and November 2016 were enrolled. A central registration method was used to document patients' demographics, clinical use, and any incidence of adverse reactions to OXA. All adverse drug reactions (ADRs) were collected and analyzed to assess causality, severity, treatment, and outcome.

Results: In total, 3687 patients were enrolled in this study. Approximately 64.6% of the patients were male, and 68.8% were aged 50-70 years, with a mean age of 55.3 years. The proportions of patients diagnosed with colorectal and gastric cancers were 59.3% and 31.6%, respectively. In this study, the overall incidence of ADRs and serious ADRs was 42.7% and 1.3%, respectively. The most common ADRs were gastrointestinal disorders (25.7%), blood disorders (21.1%), and peripheral nervous system disorders (8.0%). The serious ADRs identified were hypersensitivity reactions, thrombocytopenia, abnormal hepatic function, and leukopenia/neutropenia. The median onset of gastrointestinal toxicity, myelosuppression, peripheral neurotoxicity, and abnormal hepatic function was 1 d, 5 d, 1 d, and 14 d, respectively. The majority (84.7%) of hypersensitivity reactions were mild to moderate, and the median time to onset of these reactions was within the first 20 min of OXA infusion. Almost 88.0% of patients who experienced ADRs recovered or improved with treatment.

Conclusion: Our data suggest that OXA-induced ADRs are very common in Chinese patients with cancer; however, more attention should be paid to hypersensitivity reactions caused by OXA. This study provides a valuable reference regarding the safe application of OXA in a real-world setting.

Keywords: Chinese; cancer; oxaliplatin; post-marketing surveillance; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Severity classification of OXA induced ADRs.
Figure 2
Figure 2
Occurrence time of HSR from the start of OXA infusion.
See this image and copyright information in PMC

References

    1. Grothey A, Goldberg RM. A Review of Oxaliplatin and its Clinical Use in Colorectal Cancer. Expert Opin Pharmacother (2004) 5:2159–70. doi: 10.1517/14656566.5.10.2159 - DOI - PubMed
    1. Huang J, Zhao Y, Xu Y, Zhu Y, Huang J, Liu Y, et al. . Comparative Effectiveness and Safety Between Oxaliplatin-Based and Cisplatin-Based Therapy in Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncotarget (2016) 7(23):34824–31. doi: 10.18632/oncotarget.9189 - DOI - PMC - PubMed
    1. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. . Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2019) 17(7):855–83. doi: 10.6004/jnccn.2019.0033 - DOI - PubMed
    1. Tempero MA. NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw (2019) 17(5.5):603–5. doi: 10.6004/jnccn.2019.5007 - DOI - PubMed
    1. Taylor SE, Beck TL, Krivak TC, Zorn KK, Kelley JL, Edwards RP. Oxaliplatin Salvage for Recurrent Ovarian Cancer: A Single Institution's Experience in Patient Populations With Platinum Resistant Disease or a History of Platinum Hypersensitivity[J]. Gynecol Oncol (2014) 134(1):68–72. doi: 10.1016/j.ygyno.2014.04.039 - DOI - PubMed

LinkOut - more resources